Warning Letter — Island Kinetics, Inc. d.b.a. CoValence Laboratories
The FDA issued a Warning Letter to Island Kinetics, Inc., doing business as CoValence Laboratories, following an inspection by the Center for Drug Evaluation and Research (CDER).
This affects Island Kinetics, Inc. (d.b.a. CoValence Laboratories), its quality management personnel, and pharmaceutical companies utilizing their contract laboratory or manufacturing services.
This enforcement action indicates significant deviations from current Good Manufacturing Practice (cGMP) regulations. For firms utilizing contract facilities, this highlights the necessity of rigorous vendor oversight and the potential for regulatory risk to extend across the supply chain. Failure to address these deficiencies may lead to further enforcement actions, including potential seizure or injunction.
QA teams should conduct comprehensive audits of laboratory facilities to ensure compliance with cGMP standards. Regulatory departments should review all contract manufacturing agreements to confirm robust quality oversight is in place. Compliance officers should verify that all laboratory testing procedures and data integrity protocols meet CDER expectations.
FDA Warning Letter issued to: Island Kinetics, Inc. d.b.a. CoValence Laboratories. 07/16/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/island-kinetics-inc-dba-covalence-laboratories-726379-07162026
Open in openFDA / FDA.gov